MedPath

Influence of human plasma versus serum on transfection efficiency of mRNA nanoparticles

Conditions
Geen: het betreft fundamenteel onderzoek naar de werking van PepFect14-mRNA nanodeeltjes
-
Registration Number
NL-OMON51048
Lead Sponsor
Radboud Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
3
Inclusion Criteria

Healthy indivuals, 18-60 years of age, bodyweight: above 50 kg. Being able and
willing to complete the informed consent process.

Exclusion Criteria

Known to have a condition which results in more than minimal risk upon blood
drawing, e.g. hemophilia.
A medical condition which requires active medical intervention or monitoring to
avert serious danger to the individual's health or well-being.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main parameters are the Cy5-mRNA uptake and EGFP expression after<br /><br>transfection of cells with PF14-EGFP mRNA or PF14 with Cy5-labeled EGFP mRNA,<br /><br>in the presence of plasma or serum. Cy5 and EGFP levels will be measured by<br /><br>confocal laser scanning microscopy (CLSM).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>N.a.</p><br>
© Copyright 2025. All Rights Reserved by MedPath